Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease.

Yang X, Dai G, Li G, Yang ES.

J Mol Neurosci. 2010 May;41(1):110-3. doi: 10.1007/s12031-009-9297-1. Epub 2009 Oct 16.

PMID:
19834824
2.

Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research.

Jack CR Jr, Marjanska M, Wengenack TM, Reyes DA, Curran GL, Lin J, Preboske GM, Poduslo JF, Garwood M.

Neuroscientist. 2007 Feb;13(1):38-48. Review.

PMID:
17229974
3.

Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice.

Dewachter I, van Dorpe J, Spittaels K, Tesseur I, Van Den Haute C, Moechars D, Van Leuven F.

Exp Gerontol. 2000 Sep;35(6-7):831-41. Review.

PMID:
11053674
4.

Vaccines for Alzheimer's disease: how close are we?

Janus C.

CNS Drugs. 2003;17(7):457-74. Review.

PMID:
12751917
5.

APP transgenic mice and their application to drug discovery.

Howlett DR.

Histol Histopathol. 2011 Dec;26(12):1611-32. doi: 10.14670/HH-26.1611. Review.

PMID:
21972099
6.

Neuroprotection of Coenzyme Q10 in Neurodegenerative Diseases.

Yang X, Zhang Y, Xu H, Luo X, Yu J, Liu J, Chang RC.

Curr Top Med Chem. 2016;16(8):858-66. Review.

PMID:
26311425
7.

Co-enzyme Q10 to treat neurological disorders: basic mechanisms, clinical outcomes, and future research direction.

Salama M, Yuan TF, Machado S, Murillo-Rodríguez E, Vega JA, Menéndez-González M, Nardi AE, Arias-Carrión O.

CNS Neurol Disord Drug Targets. 2013 Aug;12(5):641-64. Review.

PMID:
23574157
8.

Coenzyme Q10 and congestive heart failure; an evolving evidence base.

Florkowski CM, Molyneux SL, Young JM.

Kardiol Pol. 2015;73(2):73-9. doi: 10.5603/KP.2015.0015. Review. No abstract available.

Supplemental Content

Support Center